Home/Pipeline/Pridopidine (with Prilenia)

Pridopidine (with Prilenia)

Amyotrophic Lateral Sclerosis (ALS)

Phase 3Active

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 3

Status

Active

Company

Ferrer

About Ferrer

Ferrer is a mission-driven, private Spanish pharmaceutical company with a diversified portfolio spanning therapeutics, diagnostics, and vaccines. It is advancing a late-stage clinical pipeline focused on neurological disorders like ALS and Progressive Supranuclear Palsy (PSP), while maintaining a commercial footprint. The company differentiates itself through its strong 'Ferrer for Good' ESG commitment, which is central to its operations and has earned it recognition as one of the World's Most Ethical Companies.

View full company profile

Therapeutic Areas

Neurology Rare Diseases

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active